Perrigo gains distribution rights to Zephrex-D and Tarex meth-blocking technology

DUBLIN - Perrigo on Tuesday announced an exclusive licensing agreement with Highland Pharmaceuticals for its Tarex methamphetamine blocking technology and the distribution rights of Zephrex-D (pseudoephedrine HCI 30 mg).  Zephrex-D was developed using the Tarex technology and has been proven to be more than 98% effective at blocking one of the more common domestic methods of illegal meth production.



"Across the country, illegal methamphetamine use continues to be a significant issue," stated Jeff Needham, EVP and president, consumer healthcare, Perrigo. "Our investment in Tarex technology is another example of Perrigo's commitment to help protect and promote healthier communities. We are committed to leveraging the Tarex technology to extend our line of meth-resistant pseudoephedrine products in the future."



Perrigo plans to integrate the Tarex technology into certain of its store brand and retailer own label pseudoephedrine HCI products in the future and will immediately begin distribution of Zephrex D to its retail customers.